# OnCo record ascent-05 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/ascent-05/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "ascent-05", "NCT05633654" ;
  schema:name "ASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63)"@en ;
  schema:description "Tests whether giving a TROP2 ADC after surgery can cure more of the triple-negative patients whose cancer survived pre-surgery chemo-immunotherapy."@en ;
  schema:url <https://onco.cc/trials/ascent-05/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05633654>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11520537/>, <https://doi.org/10.1080/14796694.2024.2357534> ;
  onco:status "recruiting" ;
  onco:phase "3" ;
  schema:startDate "2022-12-12" ;
  onco:related <https://onco.cc/ideas/idea-post-neoadjuvant-adc/>, <https://onco.cc/trials/tropion-breast03/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:terms <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/efs/> ;
  onco:trials <https://onco.cc/trials/keynote-522/> .